We intend to capitalize on our management team’s background to identify and acquire a business in the life sciences industry. In particular, we will target companies in the biotechnology sector where our management team has extensive experience with a focus on identifying target businesses in developed countries including, but not limited to, the United States […]

We intend to concentrate our efforts in identifying businesses in the media and entertainment industries, with a focus on differentiated product and service offerings. In particular, we expect to seek assets that target three broad themes: (1) innovative platforms that support evolving consumer trends; (2) next-generation technology that may unlock new markets and strong growth; and (3) traditional […]

The chromatin regulatory system orchestrates gene expression–the turning on and off of genes–which is fundamental to how all our cells function. Breakdowns in this system lead to a wide range of diseases impacting millions of patients. Understanding the mechanism of how this system works could lead to an entirely new class of therapeutics. To our […]

We intend to focus on businesses primarily operating in the health care and health care provider space in North America and Asia-Pacific. Possible targets may include hospitals or hospital networks, specialty clinics chains, chronic disease health care service providers, telemedicine/digital health providers and/or associated technology/platform enablers, or artificial intelligence/big data enabled diagnostic providers.  We believe the […]

  We intend to focus our search for an initial business combination on companies within the broader consumer technology ecosystem that are either consumer-facing or support the infrastructure of consumer applications (“apps”) with enterprise valuations in an approximate valuation range of $1.0 billion to $3.0 billion. We intend to specifically focus on companies that have created, or […]

We intend to focus our search for a target business in the energy value chain in North America with a particular focus on opportunities aligned with energy transition and sustainability themes.  Our sponsor is an affiliate of a private investment fund managed by Apollo. Leon Black, Joshua Harris and Marc Rowan, Apollo’s managing partners, have […]

  We are a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. We use our proprietary technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. This […]

We intend to capitalize on the ability of our management team to identify, acquire and manage a market-leading business that may provide opportunities for attractive risk-adjusted returns. We believe the expertise of our management team will allow us to identify potential acquisition targets with attractive risk-adjusted returns across a diverse set of industries and geographies. […]

We intend to concentrate our efforts in identifying businesses in the governance, risk, and compliance (“GRC”) and legal technology and software (collectively, “GRCL”) sectors with an enterprise value of about $750 million to $2 billion. We believe the GRCL universe is comprised of hundreds of private companies attractive for today’s public market environment. Our sponsor […]

We intend to focus our search for a target business operating in the restaurant, hospitality and related technology and service sectors (our “Target Sectors”) globally. Our management team, led by co-CEOs Dave Pace and Andy Pforzheimer, with Greg Golkin as president. and Chris Bradley as CFO, Officer, bring a unique combination of executive, operating, investing, financial and […]